Abstract 3042
Background
KS is an HHV8 related lympho-angioproliferative disease with 4 clinical settings: post-transplant, epidemic, endemic, and classic. Although several studies described the clinical course of epidemic and post-transplant KS, the lack of large cohorts of C/E KS precluded such characterization. Our study aimed to describe the clinical course of C/E KS and identify risk factors for systemic treatment (ST) initiation and response.
Methods
We performed a retrospective study including 160C/E KS (n = 131 C and n = 29 E) patients diagnosed between 1990 and 2013 in 1 French dermato-oncology center).
Results
Median age was 62.6years [IQR:54.5;72.4] and Male/Female sex ratio was 140/20. During a median follow-up of 4.8years, 14% patients did not require any treatment while 44 and 41% required local and systemic treatments respectively. Among the 66 patients who required ST, 53% had more than one line of treatment. Cumulative incidence of ST initiation after 2years of follow-up was 28.4% [95%CI:20.5.35.5], and the median time from diagnosis to ST initiation was 8.8years [95%CI:4.7;12.7]. Instantaneous risk of ST initiation decreases over time. Multivariate analysis identified 3 risk factors for ST initiation: E versus C KS (HR: 4.19 [95%CI:2.32; 7.55]), total number of lesions higher than 10 (HR: 4.68 [95%CI:2.47;8.87]), and presence of edema (HR: 1.84 [95%CI:1.02;3.33]). Best overall response (BOR) after the first-line of treatment was CR in 14%, PR in 69%, SD in 8% and PD in 9% patients. Type of first-line therapy (low dose interferon, chemotherapy or other), type of KS (E or C), age at therapy initiation and time between diagnosis and ST initiation were not associated with BOR. Given the chronic evolution of KS and the impact of ST on the quality of life, we evaluated the treatment-free interval (TFI=time between end of first-line and start of second-line) during the first 2years after ST initiation. The mean TFI was 306days [95%CI:199;413] for interferon and 422days [95%CI:320;524] for chemotherapy treated patients.
Conclusions
Our study reveals important ST initiation risk factors in C/E KS. No major efficacy difference was observed between interferon and chemotherapy, thus enabling treatment choice based on patient’s fitness.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3157 - Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)
Presenter: Yihebali Chi
Session: Poster Display session 1
Resources:
Abstract
3710 - The effect of treatment line on the efficacy of Anlotinib hydrochloride in advanced alveolar soft part sarcoma patients
Presenter: Zhiwei Fang
Session: Poster Display session 1
Resources:
Abstract
3184 - Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
798 - Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs)
Presenter: Sebastian Bauer
Session: Poster Display session 1
Resources:
Abstract
6117 - VEGFR2 and ITGA polymorphisms as novel pan-sarcoma biomarkers for sensitivity prediction as well as toxicity prevention anti-angiogenesis therapy in pediatric and young adult
Presenter: Qiyuan Bao
Session: Poster Display session 1
Resources:
Abstract
5450 - Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa.
Presenter: Roberta Sanfilippo
Session: Poster Display session 1
Resources:
Abstract
4279 - Efficacy and Safety of VEGFR2 Inhibitor Apatinib combined with chemotherapy for Sarcoma in Stage IV
Presenter: Zhiwu Ren
Session: Poster Display session 1
Resources:
Abstract
5929 - Outcomes of metastatic soft tissue sarcoma treated with Pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country
Presenter: Akhil Kapoor
Session: Poster Display session 1
Resources:
Abstract
2469 - Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma
Presenter: David Moura
Session: Poster Display session 1
Resources:
Abstract
4210 - Efficacy and safety of apatinib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
Presenter: Zhaolun Cai
Session: Poster Display session 1
Resources:
Abstract